A practical reference on secretagogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-14 and is reviewed periodically as new material appears.
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C38H49N9O5 | 五肽，C 端酰胺化 |
| 分子量 | 约 711.85 g/mol | 游离碱形式 |
| 外观 | 白色至类白色冻干粉 | 研究用材料的常见形态 |
| 溶解性 | 溶于水及 DMSO 等极性溶剂 | 建议现配现用 |
| 储存温度 | -20 °C 或更低 | 干燥、避光、限制冻融次数 |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
== Use and effects == Orally administered NMT appears to produce no psychoactive effects, likely as a result of extensive first-pass metabolism. According to Roger W. Brimblecombe and colleagues, NMT is inactive in humans, with few details provided. On the other hand, according to reports given to Alexander Shulgin and by others, NMT is active via non-oral routes. It has been said to produce psychedelic effects at doses of 50 to 120 mg by smoking or vaporization, with a duration of seconds to minutes. Based on preliminary reports, NMT is reported to produce visuals, but its effects are described as primarily spatial in nature, among other effects. NMT has also been reported to be orally active in combination with a monoamine oxidase inhibitor (MAOI).
=== Awards and honours === Scrutton was awarded the Colworth Medal in 1999 from the Biochemical Society; the Enzyme Chemistry Award (Charmian Medal) from the Royal Society of Chemistry in 2002; the Rita and John Cornforth Award from the Royal Society of Chemistry in 2009; the Interdisciplinary Prize from the Royal Society of Chemistry in 2019. Scrutton was elected a Fellow of the Royal Society (FRS) in 2020; Fellow of the Royal Society of Chemistry (FRSC) in 1996; a Fellow of the Royal Society of Biology (FRSB) in 2009; a Member of the Lister Institute in 2004. He is recipient of a number of academic awards including: Sambrooke Exhibition Prize (King's College London, University of London, 1983); William Robson Prize (King's College London, University of London, 1985); Benefactors' Scholarship (St John's College, University of Cambridge, 1985); Henry Humphreys Research Prize / Research Fellowship (St John's College, University of Cambridge, 1989).
== Signs and symptoms == The hallmark of polymyositis is weakness and/or loss of muscle mass in the proximal musculature, as well as flexion of the neck and torso. These symptoms can be associated with marked pain in these areas as well. The hip extensors are often severely affected, leading to particular difficulty in climbing stairs and rising from a seated position. The skin involvement of dermatomyositis is absent in polymyositis. Dysphagia (difficulty swallowing) or other problems with esophageal motility occur in as many as 1/3 of patients. Low grade fever and enlarged lymph nodes may be present. Foot drop in one or both feet can be a symptom of advanced polymyositis and inclusion body myositis. The systemic involvement of polymyositis includes interstitial lung disease (ILD) and heart disease, such as heart failure and conduction abnormalities. Polymyositis tends to become evident in adulthood, presenting with bilateral proximal muscle weakness often noted in the upper legs due to early fatigue while walking. Sometimes the weakness presents itself as an inability to rise from a seated position without help or an inability to raise one's arms above one's head. The weakness is generally progressive, accompanied by lymphocytic inflammation (mainly cytotoxic T cells).
=== Specialized training methods === Altitude training Ballistic training Boxing training Circuit training Complex training Cross training Endurance training Long slow distance Grip strength training Interval training Plyometrics (jump training) Power training Strength training High-intensity training Suspension training Weight training Resistance training Training to failure
Sources: en.wikipedia.org
=== Skin === Deficiencies in vitamin A and retinoic acid have been linked to an increased susceptibility to skin infection and inflammation. Vitamin A appears to modulate the innate immune response and maintains homeostasis of epithelial tissues and mucosa through its metabolite, retinoic acid (RA). As part of the innate immune system, toll-like receptors in skin cells respond to pathogens and cell damage by inducing a pro-inflammatory immune response which includes increased RA production. The epithelium of the skin encounters bacteria, fungi and viruses. Keratinocytes of the epidermal layer of the skin produce and secrete antimicrobial peptides (AMPs). Production of AMPs resistin and cathelicidin, are promoted by RA. Another way that vitamin A helps maintain a healthy skin and hair follicle microbiome, especially on the face, is by reduction of sebum secretion, which is a nutrient source for bacteria. Retinol is used topically, in often unregulated cosmetic applications, claiming to mitigate the visible effects of ageing on the skin. Clinical and histological improvement is observed, but is not maintained after application is discontinued. When applied topically there is very little systemic absorption through the skin. Retinol has been the subject of clinical studies regarding its ability to reduce fine wrinkles and roughness on the face and neck. All-trans retinol has been used in over-the-counter cosmetic products since 1984.
The official position of West Germany concerning East Germany at the outset was that the West German government was the only democratically elected, and therefore the only legitimate, representative of the German people. According to the Hallstein Doctrine, any country (with the exception of the USSR) that recognised the authorities of the German Democratic Republic would not have diplomatic relations with West Germany. In the early 1970s, Willy Brandt's policy of "Neue Ostpolitik" led to a form of mutual recognition between East and West Germany. The Treaty of Moscow (August 1970), the Treaty of Warsaw (December 1970), the Four Power Agreement on Berlin (September 1971), the Transit Agreement (May 1972), and the Basic Treaty (December 1972) helped to normalise relations between East and West Germany and led to both German states joining the United Nations. The Hallstein Doctrine was relinquished, and West Germany ceased to claim an exclusive mandate for Germany as a whole. Following the Ostpolitik, the West German view was that East Germany was a de facto government within a single German nation and a de jure state organisation of parts of Germany outside the Federal Republic. The Federal Republic continued to maintain that it could not within its own structures recognise the GDR de jure as a sovereign state under international law; while at the same time acknowledging that, within the structures of international law, the GDR was an independent sovereign state.
==== MeSH D12.776.964.775.750 – retroviridae proteins, oncogenic ==== MeSH D12.776.964.775.750.320 – fusion proteins, gag-onc MeSH D12.776.964.775.750.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.964.775.750.470 – gene products, rex MeSH D12.776.964.775.750.480 – gene products, tax MeSH D12.776.964.775.750.650 – oncogene protein gp140(v-fms) MeSH D12.776.964.775.750.710 – oncogene protein p21(ras) MeSH D12.776.964.775.750.750 – oncogene protein p55(v-myc) MeSH D12.776.964.775.750.760 – oncogene protein pp60(v-src) MeSH D12.776.964.775.750.817 – oncogene protein v-maf MeSH D12.776.964.775.750.875 – oncogene proteins v-abl MeSH D12.776.964.775.750.882 – oncogene proteins v-erba MeSH D12.776.964.775.750.883 – oncogene proteins v-erbb MeSH D12.776.964.775.750.887 – oncogene proteins v-fos MeSH D12.776.964.775.750.900 – oncogene proteins v-mos MeSH D12.776.964.775.750.903 – oncogene proteins v-myb MeSH D12.776.964.775.750.920 – oncogene proteins v-raf MeSH D12.776.964.775.750.925 – oncogene proteins v-rel MeSH D12.776.964.775.750.935 – oncogene proteins v-sis
Sources: en.wikipedia.org
两者都是 GHS-R1a 激动剂，但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度，而非绝对区分。
公开资料中它主要以研究用肽的形式出现，未获主要监管机构批准用于治疗。可得材料通常标注仅供研究使用。任何临床用途的宣称都缺少监管依据。
序列中的 Aib 与 D-2-Nal 等非天然残基可提高对肽酶的抵抗能力，并影响受体结合的构象。这类修饰在合成肽设计中较为常见。它们也使常规氨基酸分析需要额外步骤才能确认序列。
Aib 即 α-氨基异丁酸，是一种非蛋白质源氨基酸，其侧链为两个甲基。它在肽链中倾向于诱导螺旋构象并限制骨架的柔性。这种刚性被认为有助于抵抗蛋白酶切割。